Press Release Archive
February 28, 2011 - Pfizer Announces Updated, Interactive Development Pipeline
(BUSINESS WIRE)--Pfizer Inc. today provided an update to its development pipeline, available at www.pfizer.com/pipeline. The updated pipeline includes an overview of the company’s research and a list of compounds in development with targeted indication, phase of development and, for late-stage programs, mechanism of action. The company has redesigned the format of the development pipeline, providing interactive capabilities that will
(BUSINESS WIRE)--NEW YORK
(BUSINESS WIRE)--NH Citizens Health Initiative, in collaboration with Pfizer, Inc. and the New Hampshire Medical Society, is premiering two mini-documentaries detailing what it means to be a patient and a provider in a patient-centered medical home. The videos were created by The Initiative and Pfizer in an effort to describe the value and benefits of medical homes. Patient-centered medical homes put a patient’s needs at the
February 22, 2011 - U.S. Supreme Court Decision In Bruesewitz V. Wyeth A Win For Public Health
(BUSINESS WIRE)--Today, in a 6-2 decision, the U.S. Supreme Court affirmed the ruling of the U.S. Court of Appeals for the Third Circuit in favor of Pfizer’s subsidiary Wyeth, in Bruesewitz v. Wyeth. The Third Circuit determined that the National Childhood Vaccine Injury Act prevents civil suits against manufacturers of FDA-approved childhood vaccines based on a claim that a particular vaccine should have been designed differently
(BUSINESS WIRE)--PRINCETON, N.J.
February 6, 2011 - Pfizer To Acquire Ferrosan’s Consumer Healthcare Business
(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) today announced that it has entered into a definitive agreement to purchase Ferrosan’s consumer healthcare business, which includes dietary supplements and lifestyle products, from Altor 2003 Fund GP Limited. Based in Copenhagen, Ferrosan is an innovative and long-established consumer healthcare company in the Nordic region with a portfolio of leading brands. Since 1920, Ferrosan has grown to
(BUSINESS WIRE)--Amgen (NASDAQ: AMGN) and Pfizer Inc. (NYSE: PFE) today announced results from a new trial that demonstrated Enbrel® (etanercept) significantly improved scalp involvement in adult patients with moderate to severe plaque psoriasis, compared with placebo. The data will be presented today at the 69th Annual American Academy of Dermatology (AAD) meeting in New Orleans, La. “At least half
February 3, 2011 - New Co-Promotion Agreements For Rheumatoid Arthritis Products In Japan
(BUSINESS WIRE)--Pfizer Japan Inc. (“Pfizer,” headquarters: Shibuya-ku, Tokyo) and Takeda Pharmaceutical Company Limited (“Takeda,” headquarters: Chuo-ku, Tokyo) announced today an agreement to extend the period for co-promotion in Japan for the rheumatoid arthritis (RA) drug Enbrel® (generic name: etanercept). The companies also signed a new co-promotion agreement in Japan for the investigational drug tofacitinib (development code: CP-690,
(BUSINESS WIRE)--Pfizer Inc., together with its collaborator on the Alzheimer’s Immunotherapy Program, Janssen Alzheimer Immunotherapy, is pleased to announce the addition of the National Family Caregivers Association (NFCA), an organization that empowers family caregivers to act on behalf of themselves and their loved ones, as a supporter of The 7 Summits Climb for Alzheimer’s: Memories are Everything campaign. NFCA joins the campaign just
January 31, 2011 - Pfizer Announces New $5 Billion Share Repurchase Program
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its board of directors authorized a new share repurchase program of up to $5 billion of its common stock. This is in addition to approximately $4 billion of authorization remaining under its current repurchase program and increases the company’s total repurchase authorization to $9 billion. Pfizer currently expects to repurchase approximately $5 billion of its common stock during
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): ($ in millions, except per share amounts
January 31, 2011 - Pfizer Completes Tender Offer For Shares Of King Pharmaceuticals, Inc.
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has accepted for purchase all of the shares validly tendered and not validly withdrawn pursuant to its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) at a purchase price of $14.25 per share, net to the seller in cash, without interest thereon and subject to any required
(BUSINESS WIRE)--Pfizer Inc. today announced that Dr. Yvonne Greenstreet has been appointed Senior Vice President and Head of Medicines Development for the Specialty Care Business Unit, effective February 1 2011. Upon her arrival, she will assume global responsibility for leading the advancement of the development portfolio, ensuring its alignment with Specialty Care’s strategic objectives. “Yvonne has a strong
January 27, 2011 - Pfizer Chief Medical Officer Freda Lewis-Hall Named 2011 Woman Of The Year
(BUSINESS WIRE)--The Healthcare Businesswomen’s Association (HBA) announced that its 2011 “Woman of the Year” is Freda Lewis-Hall, MD, chief medical officer of Pfizer. In her distinguished 30-year career, Dr. Lewis-Hall has held leadership roles in direct patient care, academics, media, government, pharmaceuticals and biotechnology. “I am deeply honored to be named Woman of the Year by the Healthcare Businesswomen’s Association,” said Dr.
January 27, 2011 - Pfizer Announces HSR Clearance for the Acquisition of King Pharmaceuticals
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR Act) has been terminated in connection with the tender offer by its wholly-owned subsidiary, Parker Tennessee Corp., to purchase all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to
(BUSINESS WIRE)--NEW YORK
(BUSINESS WIRE)--Pfizer Inc. today announced that seven major research-based medical centers in New York City, including Rockefeller University, NYU Langone Medical Center, Memorial Sloan-Kettering Cancer Center, The Mount Sinai Medical Center, Columbia University Medical Center, Albert Einstein College of Medicine of Yeshiva University and Weill Cornell Medical College, have joined Pfizer’s Centers for Therapeutic Innovation, a network of
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp. (Parker), has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 5:00 p.m.
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp. (Parker), has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 5:00 p.m.
(BUSINESS WIRE)--Pfizer Inc. announced today that it has initiated the rolling submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for crizotinib (PF-02341066), an oral first-in-class anaplastic lymphoma kinase (ALK) inhibitor for the treatment of patients with advanced non-small cell lung cancer (NSCLC) whose tumors are ALK-positive. Pfizer expects to complete the submission in the first half of 2011
Pages
Press release archive foot note
Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.
Stay on top of Pfizer breaking news: Get News Alerts by RSS. 
Stock Quote Disclaimer
20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.
 |
If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page. |
Current Stock Price
| . |
. . |
| %Change | . | 52 Wk. High | . |
| Day High | . | 52 Wk. Low | . |
| Day Low | . | Mkt. Cap(Bil) | . |
| Open | . | ||
| Prev Close | . | Symbol | . |
| Vol. | . | Exchange | . |
Online Pfizer Press Kit
Our press kit provides information that might help you write stories or simply find out more about Pfizer.